Imagine the ocean is a giant library of secret recipes for medicines, but the books are written in a code we can't read. This project uses AI to translate that code and design a digital blueprint for the best ingredients. Then, they use a biological 'factory' to actually brew these rare compounds at scale.
Many high-value marine compounds are discovered but cannot be produced at scale because they are too rare in nature or too complex to synthesize. This leads to stalled drug candidates and missed industrial opportunities.
A digital-to-pilot pipeline combining AI-driven DNA design, digital twins, and engineered microbial chassis for the production of marine natural products.
If you are an oncology drug developer dealing with stalled candidates like Peloruside A and Pateamine A — this project developed a digital-to-pilot pipeline that enables sustainable and scalable access to these high-value compounds.
If you are a specialty enzyme manufacturer dealing with the difficulty of finding first-in-class bioactive enzymes in nature — this project developed AI-powered predictive DNA design that accelerates the discovery and production of these catalysts.
If you are a marine bio-based product startup dealing with the complexity of international biodiversity regulations — this project developed production routes that ensure compliance with Nagoya, KM-GBF, and BBNJ frameworks.
Based on available project data, specific pricing or cost figures are not provided, though the project includes techno-economic assessments to determine viability.
Yes, the project aims to demonstrate production routes at TRL 6–7, which indicates a transition from laboratory to pilot-scale environments.
Based on available project data, specific licensing terms are not listed, but the project ensures compliance with international biodiversity frameworks like Nagoya and BBNJ.
The project runs from 2026-09-01 to 2030-08-31.
The project uses engineered microbial chassis and cell-free systems to create a digital-to-pilot pipeline for scalable production.
The consortium is well-balanced for commercialization, featuring 12 partners across 9 countries. With a 33% industry ratio (4 industrial partners, including 2 SMEs), the project bridges the gap between 4 universities and 4 research institutes, ensuring that the AI-driven DNA designs are validated by industrial production capabilities.
Contact the Norwegian University of Science and Technology (NTNU)
Contact us to connect with the AIMARIA consortium for pilot partnerships.
